Anti-GP210 antibody titer as a clinical parameter that predicts the long-term outcome of primary biliary cirrhosis under ursodeoxycholic acid treatment.

被引：0
|
作者：
Nakamura, M [1 ]
Shimizu-Yoshida, Y [1 ]
Takii, Y [1 ]
Komori, A [1 ]
Yokoyama, T [1 ]
Ueki, T [1 ]
Daikoku, M [1 ]
Yano, K [1 ]
Matsumoto, T [1 ]
Yatsuhashi, H [1 ]
Ito, M [1 ]
Ishibashi, H [1 ]
机构：
[1] Natl Nagasaki Med Ctr, Clin Res Ctr, Omura, Nagasaki, Japan
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：458A / 459A
页数：2
相关论文
共 50 条
  • [1] Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis
    Nakamura, Minoru
    Komori, Atsumasa
    Ito, Masahiro
    Kondo, Hisayoshi
    Aiba, Yoshihiro
    Migita, Kiyoshi
    Nagaoka, Shinya
    Ohata, Kazuyuki
    Yano, Koji
    Abiru, Seigo
    Daikoku, Manabu
    Yatsuhashi, Hiroshi
    Shimoda, Shinji
    Ishibashi, Hiromi
    HEPATOLOGY RESEARCH, 2007, 37 : S412 - S419
  • [2] Disappearance of antimitochondrial antibody in primary biliary cirrhosis during long-term ursodeoxycholic acid treatment.
    Yamazaki, K
    Nakamura, A
    Abe, S
    Abe, K
    Suzuki, K
    Sato, S
    GASTROENTEROLOGY, 1996, 110 (04) : A1364 - A1364
  • [3] Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis
    Bogdanos, Dimitrios P.
    Liaskos, Christos
    Pares, Albert
    Norman, Gary
    Rigopoulou, Eirini I.
    Caballeria, Llorenc
    Dalekos, George N.
    Rodes, Juan
    Vergani, Diego
    HEPATOLOGY, 2007, 45 (06) : 1583 - 1583
  • [4] POSITIVE ANTI-GP210 ANTIBODIES IS A RISK FACTOR FOR POOR BIOCHEMICAL RESPONSE TO URSODEOXYCHOLIC ACID TREATMENT IN JAPANESE PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
    Nakamura, M.
    Ito, M.
    Yamamoto, K.
    Zeniya, M.
    Ohira, H.
    Hashimoto, E.
    Honda, M.
    Kaneko, S.
    Ueno, Y.
    Kikuchi, K.
    Onji, S.
    Shimoda, S.
    Takikawa, H.
    Tanaka, A.
    Komori, A.
    Yatsuhashi, H.
    Kondo, H.
    Harada, K.
    Onishi, S.
    Tsubouchi, H.
    Nakanuma, Y.
    Ishibashi, H.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S514 - S515
  • [5] Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis
    Nakamura, M
    Shimizu-Yoshida, Y
    Takii, Y
    Komori, A
    Yokoyama, T
    Ueki, T
    Daikoku, M
    Yano, K
    Matsumoto, T
    Migita, K
    Yatsuhashi, H
    Ito, M
    Masaki, N
    Adachi, H
    Watanabe, Y
    Nakamura, Y
    Saoshiro, T
    Sodeyama, T
    Koga, M
    Shimoda, S
    Ishibashi, H
    JOURNAL OF HEPATOLOGY, 2005, 42 (03) : 386 - 392
  • [6] Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis
    Azemoto, Nobuaki
    Kumagi, Teru
    Abe, Masanori
    Konishi, Ichiro
    Matsuura, Bunzo
    Hiasa, Yoichi
    Onji, Morikazu
    HEPATOLOGY RESEARCH, 2011, 41 (04) : 310 - 317
  • [7] Kinetics of anti-gp210 antibodies in primary biliary cirrhosis patients with ursodesoxycholic acid therapy
    Boissan, M
    Ballot, E
    Johanet, C
    AUTOANTIGENS AND AUTOANTIBODIES: DIAGNOSTIC TOOLS AND CLUES TO UNDERSTANDING AUTOIMMUNITY, 2000, 1 : 507 - 508
  • [8] A multicenter long-term treatment of primary biliary cirrhosis with ursodeoxycholic acid.
    Sorda, JA
    Igartua, EB
    Guma, C
    Villamil, FG
    Favaloro, F
    Krasniansky, D
    Terg, R
    HEPATOLOGY, 2000, 32 (04) : 509A - 509A
  • [9] Primary biliary cirrhosis: long-term therapy with ursodeoxycholic acid
    Poupon, R
    Corpechot, C
    Carrat, F
    Poupon, RE
    CHOLESTATIC LIVER DISEASES: THERAPEUTIC OPTIONS AND PERSPECTIVES: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 136 : 171 - 178
  • [10] Ursodeoxycholic acid and long-term survival in primary biliary cirrhosis
    Levy, C
    Angulo, P
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (02): : 269 - 270
12345